60 completed, 24 terminated, 7 unknown, 3 withdrawn. 66 Phase 2, 19 Phase 1, 12 Phase 3, 2 Not applicable, 1 Early Phase 1.
Follow ibritumomab tiuxetan: new trials by email Literature Review of ibritumomab tiuxetan trials Research Report on ibritumomab tiuxetan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2 Study IV QUZYTTIR™ (Cetirizine Hydrochloride Injection) vs V Diphenhydramine Cetirizine HCl 10 mg/mL, Diphenhydramine 50 mg/mL, anti-CD20 such as Rituximab or Paclitaxel - Oncology Patients Receiving Chemotherapy | Phase 2 | Completed | TerSera Therapeutics LLC | 34 | 2020-03-25 | 2023-10-06 |
| Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma Quality-of-Life Assessment, Rituximab, Yttrium Y-90 Ibritumomab Tiuxetan - Ann Arbor Stage I Grade 1 Follicular Lymphoma, Ann Arbor Stage I Grade 2 Follicular Lymphoma | Phase 3 | Terminated | Mayo Clinic | 20 | 2015-02-11 | 2025-07-09 |
| BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCL 90-Yttrium Ibritumomab tiuxetan, Carmustine, Etoposide - Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Phase 3 | Terminated | City of Hope Medical Center | 3 | 2015-01-01 | 2018-03-12 |
| Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Primary Central Nervous System Non-Hodgkin Lymphoma rituximab, yttrium Y 90 ibritumomab tiuxetan - Primary Central Nervous System Non-Hodgkin Lymphoma | Phase 2 | Terminated | Case Comprehensive Cancer Center | 1 | 2014-03-01 | 2020-07-24 |
| Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma rituximab, ibritumomab tiuxetan, anti-thymocyte globulin - Refractory Non Hodgkin Lymphoma, Relapsed Non Hodgkin Lymphoma | Phase 2 | Unknown | Joseph Tuscano | 20 | 2013-03-12 | 2022-11-30 |
| Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT) Rituximab, 111In Ibritumomab, Planar Scintigraphy Imaging - Leukemia, Lymphoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 20 | 2013-01-01 | 2020-05-05 |
| Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta) Zevalin, Rituximab - Follicular Lymphoma | Phase 3 | Terminated | Spectrum Pharmaceuticals, Inc | 1 | 2012-12-11 | 2021-10-04 |
| Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL belinostat, rituximab, yttrium Y 90 ibritumomab tiuxetan - Anaplastic Large Cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma | Phase 2 | Completed | University of Arizona | 5 | 2012-08-31 | 2018-08-28 |
| Study to Evaluate the Efficacy of Response-adapted Strategy in Follicular Lymphoma R-CHOP or R-bendamustine, Observation, Maintenance weekly x4 - Follicular Non-Hodgkin's Lymphoma | Phase 3 | Completed | Fondazione Italiana Linfomi - ETS | 807 | 2012-07-01 | 2022-06-21 |
| Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like Therapy Zevalin, Y-90-Zevalin, Rituximab - Diffuse Large B-cell Lymphoma, Follicle Center Lymphoma | Phase 3 | Terminated | Spectrum Pharmaceuticals, Inc | 79 | 2012-04-19 | 2021-12-16 |
| Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma Rituximab, Bortezomib,Y90 ibritumomab tiuxetan - Mantle-Cell Lymphoma | Phase 2 | Terminated | Duke University | 5 | 2012-02-01 | 2015-07-15 |
| A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL) ZEVALIN, BEAM - Relapsed Follicular Lymphoma | Phase 3 | Completed | Fondazione Italiana Linfomi - ETS | 159 | 2012-01-01 | 2026-09-09 |
| High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Fludarabine Phosphate - Post-Transplant Lymphoproliferative Disorder, Recurrent Adult Diffuse Large Cell Lymphoma | Phase 2 | Terminated | Fred Hutchinson Cancer Center | 20 | 2011-11-16 | 2021-07-20 |
| Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma Y-90-Zevalin, Moxtezafin Gadolinium, Rituximab - Non-Hodgkin's Lymphoma | Phase 2 | Terminated | Spectrum Pharmaceuticals, Inc | 5 | 2011-11-01 | 2021-10-04 |
| S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma rituximab, cyclophosphamide, doxorubicin hydrochloride - Lymphoma | Phase 2 | Completed | SWOG Cancer Research Network | 159 | 2011-09-01 | 2025-06-17 |
| ZAR2007: R-CHOP in Folicular Lymphoma Patients no Treated Previously. Consolidation With 90Y Ibritumomab Tiuxetan (Zevalin®) Versus Maintenance Treatment With Rituximab (MabThera®) Rituximab, Ibritumomab tiuxetan - Lymphoma | Phase 2 | Completed | PETHEMA Foundation | 149 | 2008-12-01 | 2020-04-28 |
| Zevalin Post-marketing Surveillance in Japan [90]Y-ibritumomab tiuxetan (Zevalin, BAY86-5128) - Non-Hodgkin's Lymphoma (NHL) | Completed | Spectrum Pharmaceuticals, Inc | 400 | 2008-09-01 | 2021-10-01 | |
| Zevalin With Non Myeloablative Allogeneic Stem Cell Transplantation in Patients With Non Hodgkin Lymphoma Rituximab, 90Y ibritumomab tiuxetan (Zevalin), Cyclophosphamide - Non-Hodgkins Lymphoma | Phase 1 / Phase 2 | Unknown | Maisonneuve-Rosemont Hospital | 20 | 2008-09-01 | 2008-12-11 |
| Zevalin Post-marketing Surveillance for Adequateness of Image Interpretation Criteria in Japan [111]In-ibritumomab tiuxetan (Zevalin, BAY86-5128) - Non-Hodgkin's Lymphoma (NHL) | Completed | Bayer | 72 | 2008-08-01 | 2011-11-24 | |
| Zevalin for Patients With Incomplete Response to Chemo Prior to Autologous Stem Cell Transplant for Multiple Myeloma indium-111-ibritumomab tiuxetan, 90Y Zevalin - Multiple Myeloma | Phase 2 | Terminated | Tufts Medical Center | 8 | 2008-04-01 | 2017-03-20 |
Showing 20 of 94. Sign in to see all of them.
Lymphoma (37) · Lymphoma, Non-Hodgkin (37) · Lymphoma, Follicular (33) · Lymphoma, Large B-Cell, Diffuse (30) · Lymphoma, Mantle-Cell (22) · Leukemia, Lymphocytic, Chronic, B-Cell (13) · Lymphoma, B-Cell, Marginal Zone (13) · Burkitt Lymphoma (9) · Lymphoma, Large-Cell, Immunoblastic (9) · Waldenstrom Macroglobulinemia (9) · Lymphoma, B-Cell (6) · Lymphoma, Large-Cell, Anaplastic (4) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Leukemia (2) · Multiple Myeloma (2)
M.D. Anderson Cancer Center (8) · National Cancer Institute (NCI) (5) · Spectrum Pharmaceuticals, Inc (5) · Bayer (4) · City of Hope Medical Center (4) · Mayo Clinic (3) · Northwestern University (3) · Beth Israel Deaconess Medical Center (2) · Biogen (2) · Fondazione Italiana Linfomi - ETS (2) · Fred Hutchinson Cancer Center (2) · Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea (2) · Lymphoma Study Association (2) · Memorial Sloan Kettering Cancer Center (2) · SWOG Cancer Research Network (2)
United States (57) · Italy (9) · France (8) · Spain (8) · Canada (7) · Belgium (5) · Germany (5) · United Kingdom (5) · Switzerland (4) · Israel (3) · Japan (3) · Netherlands (3) · Australia (2) · Austria (2) · Ireland (2)
Daniel O. Persky, MD (3) · Ajay Gopal (2) · Dolores Caballero, MD (2) · Felipe Samaniego, MD (2) · Issa F. Khouri, MD,BS (2) · Leo I. Gordon, MD (2) · Robin Joyce, MD (2) · Thomas C. Shea, MD (2) · Thomas Witzig (2) · Ahmed Galal, MD (1) · Alexandra M. Levine, MD (1) · Amrita Krishnan, MD (1) · Amrita Y. Krishnan MD, MD (1) · Amrita Y. Krishnan, MD (1)
PMID 11255275, PMID 11441933, PMID 12011122, PMID 12149300, PMID 12652460, PMID 19018755, PMID 19525191, PMID 21508413, PMID 22035417, PMID 23233718, PMID 24297953, PMID 24652994, PMID 25072780, PMID 25361987, PMID 25395425, PMID 26849853, PMID 27677906, PMID 27771496, PMID 28869931, PMID 29476021, PMID 29709062, PMID 30454872, PMID 30826465, PMID 34459702, PMID 34555839, PMID 34709880, PMID 35150296, PMID 37301631, PMID 37922989, PMID 40106688, PMID 8636765
P01CA030206 (3), 2005 (2), P30CA015083 (2), P30CA023074 (2), P30CA033572 (2), U10CA032102 (2), P01CA044991 (1), P30CA015704 (1), U01CA070019 (1), U01CA097452 (1)